Proteases: Common culprits in human skin disorders

Trends in Molecular Medicine

Volumn 20, Issue 3, 2014, Pages 166-178

  de Veer, Simon J ^a,b,c   Furio, Laetitia ^a,b   Harris, Jonathan M ^c   Hovnanian, Alain ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Allergy; Differentiation; Epidermis; Homeostasis; Inflammation; Keratinocyte

Indexed keywords

ALLERGY; DIFFERENTIATION; EPIDERMIS; HOMEOSTASIS; INFLAMMATION; KERATINOCYTE;

CELL DIFFERENTIATION; EPIDERMIS; HOMEOSTASIS; HUMANS; KERATINOCYTES; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; PROTEOLYSIS; SKIN; SKIN DISEASES;

EID: 84894477461     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.11.005     Document Type: Review

References (105)

1. Mascia F., et al. The black box illuminated: signals and signaling. J. Invest. Dermatol. 2012, 132:811-819.
2. Brattsand M., et al. A proteolytic cascade of kallikreins in the stratum corneum. J. Invest. Dermatol. 2005, 124:198-203.
3. Borgono C.A., et al. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem. 2007, 282:3640-3652.
4. Netzel-Arnett S., et al. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J. Biol. Chem. 2006, 281:32941-32945.
5. Egberts F., et al. Cathepsin D is involved in the regulation of transglutaminase 1 and epidermal differentiation. J. Cell Sci. 2004, 117:2295-2307.
6. Zeeuwen P.L., et al. The cystatin M/E-cathepsin L balance is essential for tissue homeostasis in epidermis, hair follicles, and cornea. FASEB J. 2010, 24:3744-3755.
7. Martins V.L., et al. Matrix metalloproteinases and epidermal wound repair. Cell Tissue Res. 2013, 351:255-268.
8. Tholen S., et al. Deletion of cysteine cathepsins B or L yields differential impacts on murine skin proteome and degradome. Mol. Cell. Proteomics 2013, 12:611-625.
9. Auf dem Keller U., et al. Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation. Sci. Signal. 2013, 6:rs2.
10. Sales K.U., et al. Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. Nat. Genet. 2010, 42:676-683.
11. Friis S., et al. A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation. J. Biol. Chem. 2013, 288:19028-19039.
12. Ohler A., et al. Analyzing the protease web in skin: meprin metalloproteases are activated specifically by KLK4, 5 and 8 vice versa leading to processing of proKLK7 thereby triggering its activation. Biol. Chem. 2010, 391:455-460.
13. Yamamoto M., et al. Kallikrein-related peptidase-7 regulates caspase-14 maturation during keratinocyte terminal differentiation by generating an intermediate form. J. Biol. Chem. 2012, 287:32825-32834.
14. Fortugno P., et al. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis. J. Invest. Dermatol. 2011, 131:2223-2232.
15. Deraison C., et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol. Biol. Cell 2007, 18:3607-3619.
16. Meyer-Hoffert U., et al. Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases. J. Biol. Chem. 2010, 285:32174-32181.
17. Brattsand M., et al. SPINK9: a selective, skin-specific Kazal-type serine protease inhibitor. J. Invest. Dermatol. 2009, 129:1656-1665.
18. Meyer-Hoffert U., et al. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor. PLoS ONE 2009, 4:e4372.
19. Fan B., et al. Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin. J. Biol. Chem. 2005, 280:34513-34520.
20. Lin C.Y., et al. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J. Biol. Chem. 1999, 274:18237-18242.
21. Chen Y.W., et al. Regulation of the matriptase-prostasin cell surface proteolytic cascade by hepatocyte growth factor activator inhibitor-1 during epidermal differentiation. J. Biol. Chem. 2010, 285:31755-31762.
22. Wiedow O., et al. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem. 1990, 265:14791-14795.
23. Wiedow O., et al. Antileukoprotease in psoriatic scales. J. Invest. Dermatol. 1993, 101:305-309.
24. Roupe K.M., et al. Injury is a major inducer of epidermal innate immune responses during wound healing. J. Invest. Dermatol. 2010, 130:1167-1177.
25. Kato T., et al. Cystatin A inhibits IL-8 production by keratinocytes stimulated with Der p 1 and Der f 1: biochemical skin barrier against mite cysteine proteases. J. Allergy Clin. Immunol. 2005, 116:169-176.
26. Cheng T., et al. Cystatin M/E is a high affinity inhibitor of cathepsin V and cathepsin L by a reactive site that is distinct from the legumain-binding site. A novel clue for the role of cystatin M/E in epidermal cornification. J. Biol. Chem. 2006, 281:15893-15899.
27. Schick C., et al. Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis. Biochemistry 1998, 37:5258-5266.
28. Schick C., et al. Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. J. Biol. Chem. 1997, 272:1849-1855.
29. Heiker J.T., et al. Vaspin inhibits kallikrein 7 by serpin mechanism. Cell. Mol. Life Sci. 2013, 70:2569-2583.
30. Scott F.L., et al. SerpinB6 is an inhibitor of kallikrein-8 in keratinocytes. J. Biochem. 2007, 142:435-442.
31. Blaydon D.C., et al. Mutations in CSTA, encoding Cystatin A, underlie exfoliative ichthyosis and reveal a role for this protease inhibitor in cell-cell adhesion. Am. J. Hum. Genet. 2011, 89:564-571.
32. Hartmann M., et al. Who decides when to cleave an ectodomain?. Trends Biochem. Sci. 2013, 38:111-120.
33. Weber S., et al. The disintegrin/metalloproteinase Adam10 is essential for epidermal integrity and Notch-mediated signaling. Development 2011, 138:495-505.
34. Maretzky T., et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and β-catenin translocation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9182-9187.
35. Sahin U., et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 2004, 164:769-779.
36. Adrain C., et al. Mammalian EGF receptor activation by the rhomboid protease RHBDL2. EMBO Rep. 2011, 12:421-427.
37. Franzke C.W., et al. Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. J. Exp. Med. 2012, 209:1105-1119.
38. Christova Y., et al. Mammalian iRhoms have distinct physiological functions including an essential role in TACE regulation. EMBO Rep. 2013, 14:884-890.
39. Zettl M., et al. Rhomboid family pseudoproteases use the ER quality control machinery to regulate intercellular signaling. Cell 2011, 145:79-91.
40. Maretzky T., et al. iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:11433-11438.
41. Kono M., et al. Whole-exome sequencing identifies ADAM10 mutations as a cause of reticulate acropigmentation of Kitamura, a clinical entity distinct from Dowling-Degos disease. Hum. Mol. Genet. 2013, 22:3524-3533.
42. Tharmarajah G., et al. Adam10 haploinsufficiency causes freckle-like macules in Hairless mice. Pigment Cell Melanoma Res. 2012, 25:555-565.
43. Blaydon D.C., et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am. J. Hum. Genet. 2012, 90:340-346.
44. Etheridge S.L., et al. Rhomboid proteins: a role in keratinocyte proliferation and cancer. Cell Tissue Res. 2013, 351:301-307.
45. Blaydon D.C., et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N. Engl. J. Med. 2011, 365:1502-1508.
46. Eckhart L., et al. Cell death by cornification. Biochim. Biophys. Acta 2013, 1833:3471-3480.
47. Lippens S., et al. Epidermal differentiation does not involve the pro-apoptotic executioner caspases, but is associated with caspase-14 induction and processing. Cell Death Differ. 2000, 7:1218-1224.
48. Hoste E., et al. Caspase-14-deficient mice are more prone to the development of parakeratosis. J. Invest. Dermatol. 2013, 133:742-750.
49. Hoste E., et al. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J. Invest. Dermatol. 2011, 131:2233-2241.
50. Kovalenko A., et al. Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease. J. Exp. Med. 2009, 206:2161-2177.
51. van Raam B.J., Salvesen G.S. Proliferative versus apoptotic functions of caspase-8 Hetero or homo: the caspase-8 dimer controls cell fate. Biochim. Biophys. Acta 2012, 1824:113-122.
52. Dennemarker J., et al. Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis. Oncogene 2010, 29:1611-1621.
53. List K., et al. Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J. Cell Biol. 2003, 163:901-910.
54. Leyvraz C., et al. The epidermal barrier function is dependent on the serine protease CAP1/Prss8. J. Cell Biol. 2005, 170:487-496.
55. Charles R.P., et al. Postnatal requirement of the epithelial sodium channel for maintenance of epidermal barrier function. J. Biol. Chem. 2008, 283:2622-2630.
56. Basel-Vanagaite L., et al. Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. Am. J. Hum. Genet. 2007, 80:467-477.
57. Alef T., et al. Ichthyosis, follicular atrophoderma, and hypotrichosis caused by mutations in ST14 is associated with impaired profilaggrin processing. J. Invest. Dermatol. 2009, 129:862-869.
58. Oeffner F., et al. IFAP syndrome is caused by deficiency in MBTPS2, an intramembrane zinc metalloprotease essential for cholesterol homeostasis and ER stress response. Am. J. Hum. Genet. 2009, 84:459-467.
59. Haghighi A., et al. A missense mutation in the MBTPS2 gene underlies the X-linked form of Olmsted syndrome. J. Invest. Dermatol. 2013, 133:571-573.
60. Kubo A., et al. Mutations in SERPINB7, encoding a member of the serine protease inhibitor superfamily, cause Nagashima-type palmoplantar keratosis. Am. J. Hum. Genet. 2013, 93:945-956.
61. Irvine A.D., et al. Filaggrin mutations associated with skin and allergic diseases. N. Engl. J. Med. 2011, 365:1315-1327.
62. Matsui T., et al. SASPase regulates stratum corneum hydration through profilaggrin-to-filaggrin processing. EMBO Mol. Med. 2011, 3:320-333.
63. Sakabe J., et al. Kallikrein-related peptidase 5 functions in proteolytic processing of profilaggrin in cultured human keratinocytes. J. Biol. Chem. 2013, 288:17179-17189.
64. Bonnart C., et al. Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J. Clin. Invest. 2010, 120:871-882.
65. Kamata Y., et al. Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of deiminated filaggrin into amino acids. J. Biol. Chem. 2009, 284:12829-12836.
66. Palmer C.N., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 2006, 38:441-446.
67. Kezic S., et al. Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy 2011, 66:934-940.
68. Broccardo C.J., et al. Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization. J. Allergy Clin. Immunol. 2011, 127:186-193.
69. Descargues P., et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat. Genet. 2005, 37:56-65.
70. Komatsu N., et al. Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Br. J. Dermatol. 2005, 153:274-281.
71. Igarashi S., et al. Cathepsin D, but not cathepsin E, degrades desmosomes during epidermal desquamation. Br. J. Dermatol. 2004, 151:355-361.
72. Zeeuwen P.L., et al. Colocalization of cystatin M/E and cathepsin V in lamellar granules and corneodesmosomes suggests a functional role in epidermal differentiation. J. Invest. Dermatol. 2007, 127:120-128.
73. Hachem J.P., et al. Acute acidification of stratum corneum membrane domains using polyhydroxyl acids improves lipid processing and inhibits degradation of corneodesmosomes. J. Invest. Dermatol. 2010, 130:500-510.
74. Chavanas S., et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 2000, 25:141-142.
75. Descargues P., et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J. Invest. Dermatol. 2006, 126:1622-1632.
76. -/- mice. Genes Dev. 2004, 18:2354-2358.
77. Krunic A.L., et al. Acral peeling skin syndrome resulting from a homozygous nonsense mutation in the CSTA gene encoding cystatin A. Pediatr. Dermatol. 2013, 30:e87-e88.
78. Thomas A.C., et al. Premature terminal differentiation and a reduction in specific proteases associated with loss of ABCA12 in Harlequin ichthyosis. Am. J. Pathol. 2009, 174:970-978.
79. Toomes C., et al. Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. Nat. Genet. 1999, 23:421-424.
80. Meade J.L., et al. A family with Papillon-Lefevre syndrome reveals a requirement for cathepsin C in granzyme B activation and NK cell cytolytic activity. Blood 2006, 107:3665-3668.
81. Menon G.K., et al. Lamellar body secretory response to barrier disruption. J. Invest. Dermatol. 1992, 98:279-289.
82. Hachem J.P., et al. Serine protease signaling of epidermal permeability barrier homeostasis. J. Invest. Dermatol. 2006, 126:2074-2086.
83. Martinon F., et al. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 2002, 10:417-426.
84. Ramachandran R., et al. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat. Rev. Drug Discov. 2012, 11:69-86.
85. Camerer E., et al. Local protease signaling contributes to neural tube closure in the mouse embryo. Dev. Cell 2010, 18:25-38.
86. Frateschi S., et al. PAR2 absence completely rescues inflammation and ichthyosis caused by altered CAP1/Prss8 expression in mouse skin. Nat. Commun. 2011, 2:161.
87. Demerjian M., et al. Acute modulations in permeability barrier function regulate epidermal cornification: role of caspase-14 and the protease-activated receptor type 2. Am. J. Pathol. 2008, 172:86-97.
88. Roelandt T., et al. The "caveolae brake hypothesis" and the epidermal barrier. J. Invest. Dermatol. 2009, 129:927-936.
89. Steinhoff M., et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J. Neurosci. 2003, 23:6176-6180.
90. Briot A., et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J. Exp. Med. 2009, 206:1135-1147.
91. Morizane S., et al. TH2 cytokines increase kallikrein 7 expression and function in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2012, 130:259-261.
92. Hansson L., et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J. Invest. Dermatol. 2002, 118:444-449.
93. Fortugno P., et al. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis. Hum. Mol. Genet. 2012, 21:4187-4200.
94. Stehlik C. Multiple interleukin-1β-converting enzymes contribute to inflammatory arthritis. Arthritis Rheum. 2009, 60:3524-3530.
95. Yamasaki K., et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 2006, 20:2068-2080.
96. Sorensen O.E., et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001, 97:3951-3959.
97. Yamasaki K., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat. Med. 2007, 13:975-980.
98. Yamasaki K., et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J. Invest. Dermatol. 2011, 131:688-697.
99. Lund L.R., et al. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 1999, 18:4645-4656.
100. Lee P., et al. Dynamic expression of epidermal caspase 8 simulates a wound healing response. Nature 2009, 458:519-523.
101. Kishibe M., et al. Kallikrein-related peptidase 8-dependent skin wound healing is associated with upregulation of kallikrein-related peptidase 6 and PAR2. J. Invest. Dermatol. 2012, 132:1717-1724.
102. Franzke C.W., et al. Antileukoprotease inhibits stratum corneum chymotryptic enzyme. Evidence for a regulative function in desquamation. J. Biol. Chem. 1996, 271:21886-21890.
103. Bennett K., et al. New role for LEKTI in skin barrier formation: label-free quantitative proteomic identification of caspase 14 as a novel target for the protease inhibitor LEKTI. J. Proteome Res. 2010, 9:4289-4294.
104. Amour A., et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 2000, 473:275-279.
105. Olson M.W., et al. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J. Biol. Chem. 1997, 272:29975-29983.